Directions

By Car: German Autobahn A5 from Frankfurt (North) / German Autobahn A5 from Karlsruhe (South):

  • From the A5 (Frankfurt / Karlsruhe): change to the A656 in the direction of Heidelberg
  • At the end of the German Autobahn take the left-hand lane and follow the signs for "Zoo / Chirurgie / Technologiepark"
  • Take the right-hand lane
  • After the underpass turn right immediately
  • Cross the Neckar bridge
  • Turn left at the third light into the Technology Park
  • After 50 m turn right
  • TICEBA can be found at the end of the street on the left side, Building INF 517
  • Parking can be found in front and in back of the building

By Car: German Autobahn A656 from Mannheim (West):

  • Take the A656 until it ends, and then proceed according to the directions above

By Train (Arrival in Heidelberg Hauptbahnhof):

  • Tram Line 1 (direction: "Technologiepark") or Line 4 (direction: "Handschuhsheim")
  • Exit at "Technologiepark"
  • Cross Berliner Straße (proceed towards your left as you exit the tram)
  • Turn right after 50 m
  • TICEBA can be found at the end of the street on the left side, Building INF 517

By Plane (arrival at the Frankfurt Airport):

  • Take the bus/shuttle from the airport to the Heidelberg Marriott-Hotel
  • From there, it is a 5-minute taxi ride to the Technology Park

or:

  • Take the train from the "Fernbahnhof" at the Frankfurt Airport to Heidelberg
  • Then proceed as above

or:

  • Take a rental car onto the German Autobahn A5 from Frankfurt (North)
  • Then proceed as above
News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter